Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928966 | 0.91 | FASN (0.48) | FASNALOX5PTGESPTGS1 | |
| SCHEMBL24074936 | 0.79 | PTGES (0.60) | ALOX5PTGESPTGS1PTGS2APP | |
| SCHEMBL3483215 | 0.78 | PTGES (0.37) | FASNALOX5PTGESPTGS1 | |
| SCHEMBL30450843 | 0.75 | SLC6A2 (0.42) | FASNALOX5PTGS1APPPTPN1 | |
| SCHEMBL29875200 | 0.73 | FASN (0.39) | FASNALOX5PTGES | |
| SCHEMBL29378400 | 0.71 | FASN (0.46) | FASNALOX5PTGESPTGS1 | |
| SCHEMBL23044598 | 0.71 | PTGES (0.35) | FASNALOX5PTGESPTGS1 | |
| SCHEMBL24074938 | 0.70 | PTGES (0.57) | ALOX5PTGESPTGS1PTGS2APP | |
| SCHEMBL24075655 | 0.69 | MEN1 (0.49) | ALOX5PTGESPTGS1PTGS2MAOB | |
| SCHEMBL24075568 | 0.69 | ALOX5 (0.77) | ALOX5PTGESPTGS1PTGS2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | FASN 3018/4885ALOX5 4836/4885PTGES 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.